News

AB Science Initiates Phase 3 Study of Masitinib in ALS

AB Science Initiates Phase 3 Study of Masitinib in ALS

AB Science Launches Phase 3 Study for Masitinib in ALS

AB Science SA has recently secured approvals from multiple European nations to initiate the confirmatory Phase 3 study of masitinib in amyotrophic lateral sclerosis (ALS). This pivotal study, identified as AB23005, marks an important milestone for the company, as it follows a thorough protocol validation by the European Medicines Agency (EMA) and an authorization from the FDA.

Details of the Study

The Phase 3 study will assess the efficacy and safety of masitinib, administered at a dose of 4.5 mg/kg/day combined with riluzole, compared to riluzole plus placebo over a treatment period of 48 weeks. This multicenter, randomized, double-blind, placebo-controlled study will involve 408 patients diagnosed with ALS, characterized by stable disease progression, specifically a functional decline of less than 1.1 points monthly on the ALSFRS-R scale.

Research Insights from Leading Experts

Professor Albert Ludolph, MD, PhD, from the University of Ulm, Germany, who is the principal investigator for this study, expressed optimism regarding the potential of masitinib. He highlighted that the study's design is rooted in robust clinical and preclinical data, including results from the earlier Phase 2B/3 study (AB10015). This prior research suggested a significant survival advantage in patients, which further supports the hypothesis of masitinib's effectiveness in the ALS population.

Key Features of the AB23005 Study

The design of study AB23005 emphasizes the selection of a particular patient population likely to respond favorably to masitinib. The EMA's Scientific Advisory Group on Neurology validated the criteria set forth for patient enrollment, underscoring the clinical relevance of identifying patients with a slower disease progression and without complete functional loss. This strategy aims to maximize the chances of demonstrating a positive outcome, given the substantial challenges that ALS poses to treatment.

Statistical Significance of Previous Trials

The previous AB10015 trial offered compelling evidence supporting the efficacy of masitinib, achieving statistically significant results on key endpoints recognized by regulatory authorities. The upcoming study will aim to double the patient population from that earlier study, therefore enhancing the statistical power necessary to confirm masitinib’s benefits in a larger cohort.

The Mechanism Behind Masitinib

Masitinib's action mechanism is particularly intriguing and is a focal point of its therapeutic profile. It targets mast cells and microglia, playing a crucial role in the inflammatory response associated with ALS. Preclinical models have demonstrated its ability to maintain neuromuscular function and have shown a significant reduction in neurofilament light (NfL) levels, an important biomarker for neurodegenerative diseases.

Intellectual Property and Market Positioning

The strategic positioning of masitinib in the ALS market is strengthened by robust intellectual property rights, protecting the treatment method until the late 2030s to early 2040s. This includes its designation as an orphan drug, granting it extended marketing exclusivity, which is particularly beneficial given the needs of patients facing this devastating condition.

About AB Science

Founded in 2001, AB Science is committed to the research and development of protein kinase inhibitors for a variety of challenging medical conditions. The company is headquartered in Paris and is publicly traded on Euronext Paris (ticker: AB).

Frequently Asked Questions

What is the goal of the AB23005 study?

The primary goal is to confirm the efficacy and safety of masitinib in patients with ALS over a 48-week treatment period.

How many patients will be involved in the study?

A total of 408 patients with ALS will be enrolled in the study.

What makes masitinib a promising treatment for ALS?

Masitinib targets mast cells and microglia, which are implicated in the inflammatory processes of ALS, aiming to preserve neuromuscular function.

What regulatory approvals has the study received?

The study has received critical approvals from multiple European countries as well as validation by the EMA and FDA authorization.

How does the study's design aim to maximize success?

The study focuses on patients with stable disease progression, enhancing the likelihood of demonstrating significant treatment effects.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Babe Ruth Lots Lead Morphy's $2 Million Collectibles Auction

Updated Category News Views 53

Ruth still pulls money like few names ever will, and Morphy's November 10-12 auction made that plain without any circus tricks. Three lots tied to the Yankees legend produced $136,500 within a Toys, Sports & General Collectibles sale that topped $2 million. That is not some vague nostalgia story. Buyers put real dollars behind a 1932 U.S. Caramel card, a 1933 Goudey card,...

Continue Reading
SoCalGas Data Program Puts Metering Case Into Focus

Updated Category News Views 61

Buried beneath the usual utility-company polish is a pretty sensible idea: find waste before a customer gets walloped by a bill. SoCalGas says its Advanced Meter Analytics program has helped customers avoid an estimated $11 million in unnecessary natural-gas costs since 2019. That is not a number likely to move Sempra’s earnings by itself, and nobody should pretend...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 61

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading
Africa Tech Festival Puts Trust Ahead of AI Hype Cycle

Updated Category News Views 75

Fifteen thousand people can fill a convention centre, but they cannot magically deliver a package, fund a small business, or repair harm from a bad automated decision. That rather useful dose of reality ran through the final day of Africa Tech Festival 2026 in Cape Town. The 29th edition drew more than 15,000 delegates across three days, and the strongest message was not...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 0

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Midea’s SC26 Cooling Pitch Targets AI Build Delays

Updated Category News Views 80

Heat is the uninvited partner in every AI build, and Midea is making a sensible argument that nobody gets paid for racks sitting idle while piping crews wrestle with a complicated cooling plant. At SC26 in Chicago, held November 17 through 19, the company made its North American debut for a modular prefabricated AI data-center cooling setup built around a magnetic coolant...

Continue Reading
Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 56

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 79

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
Surf City Seasons Put Vacation Rental Timing in Focus

Updated Category News Views 28

Summer’s Calendar Does the Talking School bells, not seagulls, appear to set the pace for Surf City’s rental market. Chris Rackley’s seasonal guide makes a pretty grounded point: the “best” time to visit Surf City, North Carolina, is not some universal magic week on a postcard. It depends on whether a traveler needs peak beach weather, wants elbow room, or...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading

Top 5 Most Recently Viewed Articles

Absci Corporation Shares Innovations at Key Investor Events

Updated Category News Views 144

Absci Corporation Engages Investors at Major Conferences VANCOUVER, Wash. and NEW YORK - Absci Corporation (Nasdaq: ABSI), a pioneering biotech company, is proud to announce its participation in several prestigious upcoming investor conferences. As a clinical-stage biotech, Absci is at the forefront of developing innovative therapeutics using advanced generative AI...

Continue Reading
Exciting News: Plaza Tire Service Expands to Lebanon, Missouri

Updated Category News Views 169

Expansion of Plaza Tire Service in Lebanon, Missouri Plaza Tire Service is excited to announce the opening of a new facility in Lebanon, MO. This new location enhances the brand's footprint, which already includes over 70 service centers spread across multiple states. The expansion brings accessible and reliable tire and automotive services closer to local families and...

Continue Reading
Braze's Growth Strategy: Navigating Market Challenges Ahead

Updated Category News Views 1037

Braze: A Leader in Customer Engagement Software Facing Growth Challenges Braze, Inc. (NASDAQ: BRZE), a recognized innovator in the customer engagement software sector, is currently navigating through a complex economic landscape as it strives to achieve aggressive growth targets. With its cutting-edge platform that enables businesses to analyze, segment, and interact with...

Continue Reading
Northern Venture Trust PLC Confirms New Equity Issue Details

Updated Category News Views 265

Overview of Latest Issue of Equity Northern Venture Trust PLC has taken a significant step forward with its latest equity issuance. The Company recently announced that it has allotted a total of 877,021 ordinary shares, each valued at 25p, to shareholders who opted into the Dividend Investment Scheme. The shares were made available at a subscription price of 58.3p each,...

Continue Reading
The Essential Role of Automation in Cybersecurity Management

Updated Category News Views 187

Understanding the Rising Importance of Automation in Cybersecurity As digital ecosystems continue to expand, organizations face a growing challenge in managing firewall policies across hybrid and multi-cloud environments. The increasing complexity of these systems demands innovative approaches to cybersecurity, and automation has emerged as a critical solution. By...

Continue Reading